Hologic to Join Nasdaq-100 Index®
PRNewswire-FirstCall
BEDFORD, Mass.

BEDFORD, Mass., Dec. 19, 2007 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX) a diversified medical technologies company specializing in diagnostic imaging products and interventional devices dedicated to serving the healthcare needs of women, today announced that it has been notified by Nasdaq® that the company will be added to the Nasdaq-100 Index® effective

At the opening of trading on Monday, December 24, 2007. The Nasdaq-100 Index® includes 100 of the largest domestic and international non-financial securities listed on Nasdaq® based on market capitalization across major industry groups.

"Hologic is delighted to have been selected for the Nasdaq-100 index®," said Jack Cumming, Chief Executive Officer. "We are focused on strengthening our market leadership, creating more value for our customers and shareholders and most importantly, helping to enhance the healthcare needs of women worldwide."

About Hologic, Inc.

Hologic, Inc. is a diversified diagnostic and medical product and device company dedicated to serving the healthcare needs of women. Historically, we have developed, manufactured and marketed products focused on mammography, breast care and osteoporosis assessment. In October 2007, we completed our business combination with Cytyc Corporation, a company that develops, manufactures and markets a complementary product line covering a range of cancer and women's health applications, including cervical cancer screening, treatment of excessive menstrual bleeding, and radiation treatment of early- stage breast cancer. As a result of our business combination with Cytyc, we have become one of the largest companies in the world focused on creating innovative and clinically effective advanced technologies in women's health. For more information visit www.hologic.com.

Nasdaq® and Nasdaq-100 Index® are registered trademarks of the Nasdaq Stock Market.


Contact:
Glenn Muir
Executive Vice President and CFO
Hologic, Inc.
Tel: 781.999.7300


Frances Crecco
Director, Investor Relations
Hologic, Inc.
fcrecco@hologic.com
Tel: (781) 999-7377

 

SOURCE: Hologic, Inc.